XSTOSTABL
Market cap1mUSD
Dec 23, Last price
0.41SEK
1D
3.02%
1Q
-34.92%
IPO
-94.35%
Name
Stayble Therapeutics AB
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
23.64%
Rev. gr., 5y
%
Revenues
0k
Net income
-24m
L-2.02%
CFO
-24m
L-5.42%
Profile
Stayble Therapeutics AB (publ) develops injectable treatment for chronic low back pain triggered by disc degeneration. The company develops STA363, a minimally invasive single injection of the drug into the disc that targets chronic low back pain. Stayble Therapeutics AB (publ) was incorporated in 2015 and is based in Gothenburg, Sweden.
Valuation
Title SEK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||
Revenues | ||||||||
Cost of revenue | 9,145 | |||||||
Unusual Expense (Income) | ||||||||
NOPBT | (9,145) | |||||||
NOPBT Margin | ||||||||
Operating Taxes | (298) | (50) | ||||||
Tax Rate | ||||||||
NOPAT | 298 | (9,095) | ||||||
Net income | (23,737) -2.02% | (24,227) 101.21% | (12,041) -24.98% | |||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | 31,816 | 36,349 | ||||||
BB yield | -407.57% | -40.42% | ||||||
| Debt | ||||||||
Debt current | ||||||||
Long-term debt | 850 | 850 | 850 | |||||
Deferred revenue | ||||||||
Other long-term liabilities | ||||||||
Net debt | (13,229) | (11,996) | (36,617) | |||||
| Cash flow | ||||||||
Cash from operating activities | (23,537) | (24,886) | (9,633) | |||||
CAPEX | ||||||||
Cash from investing activities | 1,000 | (1,000) | ||||||
Cash from financing activities | 24,963 | 1 | 36,155 | |||||
FCF | 299 | (9,019) | ||||||
| Balance | ||||||||
Cash | 14,079 | 12,846 | 37,466 | |||||
Long term investments | 1,000 | |||||||
Excess cash | 14,079 | 12,846 | 37,467 | |||||
Stockholders' equity | (17,690) | (22,726) | (10,290) | |||||
Invested Capital | 35,048 | 38,858 | 50,948 | |||||
ROIC | 0.66% | |||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | 25,763 | 14,228 | 14,228 | |||||
Price | 0.30 -92.43% | 4.00 -36.71% | 6.32 -19.58% | |||||
Market cap | 7,806 -86.28% | 56,914 -36.71% | 89,923 28.33% | |||||
EV | (5,423) | 67,521 | 63,474 | |||||
EBITDA | (9,145) | |||||||
EV/EBITDA | ||||||||
Interest | 28 | 57 | ||||||
Interest/NOPBT | ||||||||